Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.23|
|52 Week High||AU$0.054|
|52 Week Low||AU$0.30|
|1 Month Change||-14.82%|
|3 Month Change||12.20%|
|1 Year Change||259.38%|
|3 Year Change||139.58%|
|5 Year Change||91.67%|
|Change since IPO||-99.68%|
Recent News & Updates
We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?
Yatomi-Clarke Lee has been the CEO of Prescient Therapeutics Limited ( ASX:PTX ) since 2016, and this article will...
|PTX||AU Biotechs||AU Market|
Return vs Industry: PTX exceeded the Australian Biotechs industry which returned 1.5% over the past year.
Return vs Market: PTX exceeded the Australian Market which returned 20.2% over the past year.
Stable Share Price: PTX is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: PTX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase II clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. Prescient Therapeutics Limited has a collaboration agreement with Carina Biotech to develop cell therapies.
Prescient Therapeutics Fundamentals Summary
|PTX fundamental statistics|
Is PTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PTX income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0064|
|Net Profit Margin||-349.97%|
How did PTX perform over the long term?See historical performance and comparison
Is Prescient Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PTX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PTX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PTX is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: PTX is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PTX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PTX is overvalued based on its PB Ratio (7.3x) compared to the AU Biotechs industry average (4.9x).
How is Prescient Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Prescient Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Prescient Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PTX is currently unprofitable.
Growing Profit Margin: PTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PTX is unprofitable, and losses have increased over the past 5 years at a rate of 13.4% per year.
Accelerating Growth: Unable to compare PTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).
Return on Equity
High ROE: PTX has a negative Return on Equity (-20.31%), as it is currently unprofitable.
How is Prescient Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: PTX's short term assets (A$17.6M) exceed its short term liabilities (A$514.7K).
Long Term Liabilities: PTX's short term assets (A$17.6M) exceed its long term liabilities (A$25.0K).
Debt to Equity History and Analysis
Debt Level: PTX's debt to equity ratio (0.8%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if PTX's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PTX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: PTX has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 7.4% each year.
What is Prescient Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PTX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PTX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Steven Lee Yatomi-Clarke has been Chief Executive Officer and Managing Director of Prescient Therapeutics Limited since February 15, 2016. Mr. Yatomi-Clarke has been Director of Prescient Therapeutics...
CEO Compensation Analysis
Compensation vs Market: Steven's total compensation ($USD593.74K) is above average for companies of similar size in the Australian market ($USD302.72K).
Compensation vs Earnings: Steven's compensation has increased whilst the company is unprofitable.
Experienced Management: PTX's management team is considered experienced (4.3 years average tenure).
Experienced Board: PTX's board of directors are considered experienced (6.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Prescient Therapeutics Limited's employee growth, exchange listings and data sources
- Name: Prescient Therapeutics Limited
- Ticker: PTX
- Exchange: ASX
- Founded: 1986
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$154.702m
- Shares outstanding: 644.59m
- Website: https://ptxtherapeutics.com
- Prescient Therapeutics Limited
- 100 Albert Road
- Level 4
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 07:04|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.